Victor E. Velculescu

The paper identifies widespread mosaic structural variants in normal human tissues and tumors, with repeat-mediated variants impacting functional elements and enabling noninvasive tumor monitoring through cell-free DNA.

This study identifies a p53 mutation-specific immunotherapy strategy for ovarian cancer by targeting AREG and PD-L1, showing efficacy in mouse models and patient-derived organoids.

This study tracks ctDNA and immune cell changes in lung cancer patients on immunotherapy to identify molecular responses and immune-related toxicities.

This study identifies molecular and immune features associated with response to anti-PD-(L)1 therapy in NSCLC using a cohort of 393 patients.

The paper identifies inherited rare, deleterious ATM variants as risk factors for lung adenocarcinoma, showing increased odds ratios in case-control studies and population cohorts.

This study evaluates machine learning methods for predicting peptide-MHC Class I binding affinities, finding that MHCnuggets performs similarly to existing methods but is faster and handles variable-length peptides.